We are live on ! Find out more
SBFM icon

Sunshine Biopharma

2 hedge funds and large institutions have $415K invested in Sunshine Biopharma in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2 → 2 (0)

6.3% less ownership

Funds ownership: 11.38% → 5.08% (-6.3%)

100% less capital inflows, than outflows

Capital inflows: $0 | Capital outflows: $537K

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Armistice Capital
Armistice Capital
New York
-$537K

SBFM Hedge Fund Activity: Q3 2023 in Review

2 of the 6,318 institutional investors tracked by Wall St. Rank reported a position in Sunshine Biopharma (SBFM) for Q3 2023, worth a combined $415K — down 67% from $1.25M a quarter earlier.

Fund positioning in SBFM was balanced in Q3 2023: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.

The largest seller was Armistice Capital, cutting an estimated $537K.

  • 2 institutional investors held Sunshine Biopharma (SBFM) as of Q3 2023, unchanged from Q2 2023.
  • Funds reported $415K of Sunshine Biopharma stock for Q3 2023, down 67% quarter-over-quarter.
  • 0 funds opened new Sunshine Biopharma positions in Q3 2023 and 0 closed out.
  • The largest Sunshine Biopharma seller in Q3 2023 was Armistice Capital, an estimated $537K sold.

Based on aggregated 13F filings for Q3 2023.